Published in Cytometry on January 01, 1995
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol (2000) 4.19
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol (1997) 3.10
Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2004) 2.03
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A (2001) 1.65
Comparative genomic hybridisation. Mol Pathol (1999) 1.56
Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol (1997) 1.44
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer (2009) 1.33
A new strategy for cryptic telomeric translocation screening in patients with idiopathic mental retardation. J Med Genet (1998) 1.33
Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet (2011) 1.18
Comparative genomic hybridization in clinical cytogenetics. Am J Hum Genet (1995) 1.15
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (1997) 1.10
Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol (2001) 1.07
Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer (1997) 0.95
Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn (2001) 0.94
Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. Am J Pathol (2007) 0.85
Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol (2000) 0.82
Exceptional minute sex-specific region in the X0 mammal, Ryukyu spiny rat. Chromosome Res (2007) 0.80
Advanced molecular cytogenetics in human and mouse. Expert Rev Mol Diagn (2004) 0.78
Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer (2000) 0.77
Mosaic supernumerary ring chromosome 19 identified by comparative genomic hybridisation. J Med Genet (1998) 0.77
Comparison of sequencing based CNV discovery methods using monozygotic twin quartets. PLoS One (2015) 0.75
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (1992) 16.38
Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A (1986) 12.92
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 8.91
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (1997) 8.05
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 6.08
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer (1994) 5.52
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet (2001) 4.96
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet (2000) 4.13
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res (1995) 3.98
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst (1980) 3.75
Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn (2000) 3.59
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A (1992) 3.25
Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A (1983) 3.14
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst (2000) 3.12
E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol (1997) 3.10
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer (1971) 3.04
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res (2001) 2.69
Genetic analysis using genomic representations. Proc Natl Acad Sci U S A (1998) 2.52
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev (1995) 2.41
The proximity of DNA sequences in interphase cell nuclei is correlated to genomic distance and permits ordering of cosmids spanning 250 kilobase pairs. Genomics (1989) 2.39
Chromosome measurement and sorting by flow systems. Proc Natl Acad Sci U S A (1975) 2.37
"Total therapy" studies of acute lymphocytic leukemia in children. Current results and prospects for cure. Cancer (1972) 2.28
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG)n. Nucleic Acids Res (1990) 2.23
Genome screening by comparative genomic hybridization. Trends Genet (1997) 2.23
High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol (1999) 2.22
Cell cycle analysis by flow cytometry. Methods Enzymol (1979) 2.18
Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood (1971) 2.18
Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer (2001) 2.17
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A (2001) 2.16
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res (2000) 2.13
Segmentation of confocal microscope images of cell nuclei in thick tissue sections. J Microsc (1999) 2.12
Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol (1993) 2.09
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res (2001) 2.03
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med (1993) 1.99
Prevention of central nervous system leukemia by irradiation. Cancer (1973) 1.96
'Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone': twenty years later. Leukemia (2009) 1.95
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94
Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res (1994) 1.93
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem (1999) 1.92